Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation

Area of Science:

• Immunology
• Cancer Biology
• Pharmacology

Background:

• Loss-of-function polymorphism in formyl peptide receptor 1 (FPR1) compromises dendritic cell (DC) migration.
• This defect weakens immunosurveillance and accelerates epithelial cancer development.
• A mouse model with a human-mimetic FPR1 mutation replicates the DC defect.

Purpose of the Study:

• To identify therapeutic strategies to correct FPR1-associated DC dysfunction.
• To investigate the role of mitogen-activated protein kinase (MAPK) p38α in FPR1-mediated immune defects.
• To evaluate the efficacy of MAPK p38α inhibitors in restoring anti-cancer immunity and normalizing carcinogenesis.

Main Methods:

• Genetic and pharmacological screening of type 1 conventional DCs (cDC1) with mutated FPR1.
• In vitro and in vivo testing of small-molecule MAPK p38α inhibitors.
• Assessment of anti-cancer chemotherapy and immune checkpoint blockade responses in mouse models.
• Evaluation of colorectal carcinogenesis in mice with altered FPR1 function.

Main Results:

• MAPK p38α inhibitors were identified as effective in correcting the FPR1 defect in cDC1.
• Inhibitors restored function of FPR1-deficient or mutated cDC1 in vitro and in vivo.
• Pharmacological inhibition of MAPK p38α normalized anti-cancer responses and reduced accelerated colorectal carcinogenesis in mice.

Conclusions:

• MAPK p38α inhibition represents a promising therapeutic approach for FPR1-related immune dysfunction and associated cancers.
• Restoring DC function via MAPK p38α inhibition can enhance anti-cancer chemotherapy and immunotherapy efficacy.
• Targeting MAPK p38α offers a strategy to normalize immune surveillance and combat cancer development linked to FPR1 defects.